articleTop 1% cited
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Journal of Clinical Oncology · 1999 · Vol. 17(9) · pp. 2639–2639
Melody Cobleigh✉(Kaiser Permanente San Francisco Medical Center)Charles L. Vogel(Kaiser Permanente San Francisco Medical Center)Debu Tripathy(Kaiser Permanente San Francisco Medical Center)Nicholas J. Robert(Kaiser Permanente San Francisco Medical Center)Suzy Scholl(Kaiser Permanente San Francisco Medical Center)Louis Fehrenbacher(Kaiser Permanente San Francisco Medical Center)Janet Wolter(Kaiser Permanente San Francisco Medical Center)Virginia Paton(Kaiser Permanente San Francisco Medical Center)Steven Shak(Kaiser Permanente San Francisco Medical Center)Gracie Lieberman(Kaiser Permanente San Francisco Medical Center)Dennis J. Slamon(Kaiser Permanente San Francisco Medical Center)
Abstract
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Side effects that are commonly observed with chemotherapy, such as alopecia, mucositis, and neutropenia, are rarely seen.
HER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyLung Cancer Research StudiesMedicineChillsMetastatic breast cancerAdverse effectInternal medicineBreast cancerChemotherapyResponse Evaluation Criteria in Solid TumorsCancerOncology
MeSH terms
AdultAgedAged, 80 and overAntibodies, MonoclonalBreast NeoplasmsFemaleHeart DiseasesHumansMiddle AgedQuality of LifeTime FactorsMultivariate AnalysisConfidence IntervalsDisease ProgressionDisease-Free Survival
Funding
- Genentech
Citations
2,788
FWCI
48.32
field-weighted impact
References
27
Percentile
100%
vs. same field & year
Citations per year
Cited by
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology · 2002 · 2,949 citations
<b>Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin</b>
Molecular Biology of the Cell · 2004 · 487 citations
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
Breast Cancer Research and Treatment · 2008 · 802 citations
Perspectives on cancer therapy-induced mucosal injury
Cancer · 2004 · 1,401 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · 1,856 citations
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Annals of Oncology · 2020 · 963 citations
Tumor targeting via EPR: Strategies to enhance patient responses
Advanced Drug Delivery Reviews · 2018 · 1,186 citations
References
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
Annals of Internal Medicine · 1979 · 2,419 citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science · 1987 · 11,680 citations
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
JNCI Journal of the National Cancer Institute · 1993 · 15,705 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.